Knockdown of HDAC6 or inhibition of HDAC6 activity by HDAC6-specific inhibitor tubastatin A in NSCLC cell lines A549 and H292 sensitized the cells to cisplatin treatment. This evidence concerns the gene HDAC6 and non-small cell lung carcinoma.